FindTrial
Sign In

A study for medication therapy management of warfarin after cardiac valve surgery

A study for medication therapy management of warfarin after cardiac valve surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024873
Enrollment
Unknown
Registered
2019-08-01
Start date
2019-08-15
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart valvular disease

Interventions

MTM group:pharmasist-led medication therapy management
control group:traditional management

Sponsors

Beijing Anzhen Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Aged 18-65, heart valve replacement operation, warfarin should be taken for more than 1 year and the informed consent has been signed

Exclusion criteria

Exclusion criteria: Patients with severe complications; Patients with severe hepatic and renal insufficiency; Patients with diseases of the blood system; Patients with malignant tumors; Patients that need to take other antithrombotic drugs; Patients that cannot comply with the study

Design outcomes

Primary

MeasureTime frame
TTR;—

Secondary

MeasureTime frame
bleeding events;Thrombotic events;—

Countries

China

Contacts

Public ContactLin Yang

Beijing Anzhen Hospital, Capital Medical University

linyang3623@163.com+86 010-64456609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026